answerEntity: Hirokazu Nakayama
graph: {'nodes': [{'type': 'QUESTIONS_ENTITY', 'name_': 'Q17', 'id': 0, 'label': 'Japan'}, {'type': 'INTERNAL', 'name_': 'Q15754240', 'id': 1, 'label': 'Biological and Pharmaceutical Bulletin'}, {'type': 'ANSWER_CANDIDATE_ENTITY', 'name_': 'Q87197438', 'id': 2, 'label': 'Hirokazu Nakayama'}, {'type': 'INTERNAL', 'name_': 'Q87197441', 'id': 3, 'label': 'Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria'}], 'links': [{'name_': 'P17', 'source': 0, 'target': 0, 'label': 'country'}, {'name_': 'P495', 'source': 1, 'target': 0, 'label': 'country of origin'}, {'name_': 'P1433', 'source': 3, 'target': 1, 'label': 'published in'}, {'name_': 'P50', 'source': 3, 'target': 2, 'label': 'author'}]}